Quarter
Charts

ZYVERSA THERAPEUTICS, INC.

ZVSA

CIK 0001859007 · Quarterly mode · latest period FY2025 (Q3) (ending 2025-09-30) · sourced from SEC EDGAR

At a glance · FY2025 (Q3)

Revenue
$0
Gross Profit
$0

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    100ROIC 1040.7% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.03 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover -0.05x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Op Margin 15799.1% · trend -1575233.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Stock-based comp (TTM)
$223K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$348K
everything owned
Total liabilities
$13M
everything owed
Stockholders' equity
$-12M
shareholder claim

Recent performance · 21 quarters

Revenue
$-131K
Net Income
$-20M
Free Cash Flow↑+53.1% +$2M
$-2M
Operating Margin
15799.1%

Drill down

ZVSA Sankey

See ZYVERSA THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ZVSA Charts

21 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ZVSA Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics